Sun Yat-sen University Cancer Center: Guangzhou's Global Leader in Oncology

If you're looking for cancer treatment in southern China, Sun Yat-sen University Cancer Center (中山大学肿瘤防治中心) in Guangzhou is the undisputed leader. As one of China's earliest and largest integrated cancer centers, SYSUCC has been at the forefront of oncology since its founding in 1964. It's particularly well-known for its work in nasopharyngeal carcinoma — a cancer with unusually high prevalence in southern China — which has made the center a global authority on the disease.

SYSUCC Overview

• Grade 3A — China's highest hospital tier
• Two campuses: Yuexiu Campus (651 Dongfeng East Road) and Huangpu Campus, Guangzhou
• Founded 1964 — one of China's first comprehensive cancer centers
• Full-spectrum oncology: Surgery, radiation, chemotherapy, immunotherapy, targeted therapy, clinical trials
• Particular strengths: Nasopharyngeal carcinoma, thoracic oncology, breast oncology, colorectal oncology, hepatobiliary oncology, lymphoma

Global Leadership in Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal carcinoma is relatively rare in Western countries but common in southern China. As a result, SYSUCC has developed world-leading expertise. The center has published extensively in top journals including The Lancet Oncology and Journal of Clinical Oncology, established international staging systems, and pioneered treatment protocols adopted globally.

Comprehensive Cancer Care

Surgical Oncology

SYSUCC surgeons perform the full range of cancer surgeries including minimally invasive and robotic-assisted approaches. The center is experienced in complex resections for thoracic, GI, hepatobiliary, and head and neck cancers.

Radiation Oncology

State-of-the-art radiation equipment including IMRT, IGRT, SBRT, and proton therapy. The center is one of China's most experienced in advanced radiation techniques.

Medical Oncology & Immunotherapy

Access to the latest chemotherapy, targeted therapy, and immunotherapy agents. The center conducts numerous clinical trials, offering patients access to emerging treatments.

Clinical Trials

SYSUCC runs one of China's most active clinical trial programs, covering drug development, treatment protocols, and diagnostic innovations. International patients may be eligible for trial participation.

Accessing SYSUCC as an International Patient

SYSUCC treats a significant number of patients from Southeast Asia, particularly for cancers that are prevalent in the region. The hospital does not yet have a dedicated international medical department with the same scope as Beijing/Shanghai hospitals, but it does accept international patients:

• WeChat booking: Search "中山大学肿瘤防治中心" → 预约挂号 (register with passport)
• Phone: 020-87348000 (Monday–Friday, 8:00–17:30)
• On-site: Self-service kiosks accept passports; registration counter assistance available
• Consultation fees: ¥10–500 for general to specialist consultations
• Language: Some doctors communicate in basic English. External translation services recommended for complex cases.

Who Should Choose SYSUCC?

• Nasopharyngeal carcinoma — SYSUCC is a global authority
• Southeast Asian patients — Guangzhou's location and transportation links make it the most convenient major cancer center for patients from Vietnam, Thailand, Indonesia, Malaysia, and the Philippines
• Liver cancer patients — A leading center with strong surgical and interventional oncology programs, serving many patients from Southeast Asia where liver cancer rates are high
• Clinical trial candidates — Active clinical trial program offering access to emerging therapies
• Cantonese-speaking patients — The hospital serves a Cantonese-speaking region, which may be relevant for patients from Hong Kong, Macau, or overseas Chinese communities

The Bottom Line

Sun Yat-sen University Cancer Center is southern China's premier cancer hospital, with specific global authority in nasopharyngeal carcinoma. For patients from Southeast Asia, its location in Guangzhou offers convenient access to world-class oncology care. While the international patient infrastructure is less developed than top Beijing/Shanghai hospitals, the clinical expertise is world-class.